<DOC>
	<DOCNO>NCT02520219</DOCNO>
	<brief_summary>The aim study evaluate anti-tumor safety efficacy endostar®（Human recombinant endostatin injection）combined traditional GDP （gemcitabine+dexamethasone+cis-platinum）chemotherapy newly diagnose relapse PTCL ( aggressive peripheral T-cell lymphoma ) patient phase II clinical study .</brief_summary>
	<brief_title>Endostar Aggressive Treatment Peripheral T-cell Lymphoma ( PTCL ) Phase II Clinical Study</brief_title>
	<detailed_description>Endostar conventional drug treatment advance non-small cell lung cancer , nowadays , Endostar use variety extra-pulmonary tumor treatment clinical.Some basic experiment clinical research confirm Endostar restitute tumor stability cyclophosphamide rituximab treatment . The aim study evaluate anti-tumor safety efficacy endostar newly diagnose relapse PTCL patient base chemotherapy combine conventional GDP.This multi-center , open , randomized-controlled , phase II clinical study . Following run-in period , approximately 60 subject randomly assign conventional chemotherapy treatment group , endostar conventional chemotherapy treatment group 1 year . After 1 year treatment period , subject two treatment arm follow 1 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Newly diagnose relapse PTCL patient pathology , / cytology examination , require receive chemotherapy ; 2 . At least 1 single size measurable lesion , CT , MRI , Bultrasound scan PETCT scan show 15mm； 3 . Physical condition good : ECOG score 02 points； 4 . The expected survival time 3 months； 5 . Age 18 year old , unlimited gender； 6 . Fit chemotherapy indication basic requirement , include normal peripheral hemogram , obvious abnormal function heart , liver kidney , normal ECG ; great trauma without healing； The test indicator must fit following requirement : Cardiac ultrasound LVEF≥50 % ； Peripheral blood：WBC≥3.5×109/L，PLT≥70×109/L，Hb≥80g/L Renal function：Cr≤2.0×UNL（Upper limit normal value） Liver function：BIL≤2.0×UNL，ALT/AST≤2.5×UNL 7 . No serious allergic reaction biological agent , especially E. coli gene engineering products； 8 . Voluntary participation , good compliance , cooperate experimental observation , sign write informed consent。 1 . Inert T cell lymphoma ( mycosis fungoides /Sezary syndrome ) , ALK positive anaplastic large cell lymphoma； 2 . Patients receive chemotherapy drug past ; 3 . Pregnant woman , lactate woman , fertility take contraceptive measures； 4 . Patients serious uncontroled acute infection ; suppurative chronic infection unhealing wound； 5 . Patients original serious heart disease , include : highrisk cardiac arrhythmia congestive heart failure , uncontroled instability angina , myocardial infarction severe heart valve disease intractable hypertension； 6 . Patients less control nervous , mental illness mental disorder , poor compliance , description treatment response； 7 . Patients primary central nervous system lymphoma lymphoma involve central nervous system； 8 . Patients abnormal coagulation function severe thrombosis ; 9 . Patients participate clinical trials； 10 . The researcher consider patient trial。</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Peripheral T-cell lymphoma , Endostar</keyword>
</DOC>